Just yesterday Gilead Sciences (NASDAQ:GILD) traded 0.85% higher at $78.42. (NASDAQ:GILD) has infringed, and continues to infringe, on the university’s intellectual property rights by selling three medicines that contain the drug sofosbuvir. The stock now has an average rating of “Buy” and a consensus price target of $106.74.
Advertisement
At $78 per share, Gilead’s stock price has retrenched to where it traded in April 2014. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. The Hedge Fund company now holds 143 shares of GILD which is valued at $11,391.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700.
Receive Gilead Sciences News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences with MarketBeat.com’s FREE daily email newsletter.
Many Wall Street Analysts have commented on Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, July 25th. Post opening the session at $79.65, the shares hit an intraday low of $77.63 and an intraday high of $79.7 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red. Gilead Sciences’s 50-day average is $81.86 and its 200-day moving average is $87.05. The stock has a market cap of $103.43 billion and a P/E ratio of 6.88. At present, 11 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. Revenue came in at 7.78B versus consensus estimate of 7.77B. Now the stock has been rated as “Buy” from 14 Analysts. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. It has a dividend yield of 2.40%. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, July 1st.
During the a year ago Gilead Sciences’s shares have decreased by -24.19% from 103.13 to 78.18. The disclosure for this sale can be found here. Following the completion of the sale, the executive vice president now owns 63,122 shares of the company’s stock, valued at approximately $5,246,700.64. The University of Minnesota is suing Gilead Sciences Inc., alleging the pharmaceuticals firm’s lucrative Hepatitis C drugs infringe on a university patent. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 48.28 and 64.57. Bank of Montreal Can acquired a new stake in Gilead Sciences during the second quarter worth about $427,750,000. Finally, Riverhead Capital Management LLC raised its position in shares of Gilead Sciences by 84.2% in the first quarter. Jefferies Group analyst B. Abrahams now forecasts that the firm will post earnings per share of $2.89 for the quarter, down from their prior forecast of $3.03.
Advertisement
Gilead Sciences, Inc is a research-based biopharmaceutical company.
